CLAIMS

1. 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or pharmaceutically acceptable salts thereof for use in prevention, reduction, or treatment of emotional blunting in a patient.

2. 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or pharmaceutically acceptable salts thereof for use according to claim 1, wherein said patient is suffering from a CNS disease or disorder.

3. 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or pharmaceutically acceptable salts thereof for use according to claim 1 or 2, wherein said patient experiences emotional blunting as part of a CNS disease or disorder.

4. 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or pharmaceutically acceptable salts thereof for use according to claim 2 or 3, wherein said patient has previously received, or is still receiving, medication for the treatment of said CNS disease.

5. 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or pharmaceutically acceptable salts thereof for use according to claim 4, said medication resulting in symptoms and signs of emotional blunting, wherein said medication was ceased, or has to be ceased, due to emotional blunting.

6. 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or pharmaceutically acceptable salts thereof for use according to any one of claims 2-3, wherein said CNS disease or disorder is selected from psychiatric disorders, such as, psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, catatonia, delusional disorder; mood disorders, such as bipolar disorder, cyclothymic disorder, major depression, dysthymia, premenstrual dysphoric disorder; and substance use disorders.

7. 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or pharmaceutically acceptable salts thereof for use according to claims 4-5, wherein said CNS disease or disorder is selected from PTSD, depression, including Major Depressive Disorder (MDD) and Major Depressive Episodes (MDE), cognitive impairment, schizophrenia, psychosis, Parkinson's disease, autism, vascular dementia, and multiple system atrophy.

8. 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or pharmaceutically acceptable salts thereof for use according to any one of claims 2-7, wherein said CNS disease or disorder is selected from major depressive disorder and schizophrenia.

9. 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or pharmaceutically acceptable salts thereof for use according to any one of claims 4-5, wherein said medication is a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI).

10. 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or pharmaceutically acceptable salts thereof for use according to any one of claims 4-5, wherein said CNS disease or disorder is selected from major depressive disorder and schizophrenia, and wherein said medication is a selective serotonin reuptake inhibitors inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI).

11. 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or pharmaceutically acceptable salts thereof for use according to any one of claims 9-10, wherein said medication is selected from Escitalopram, Fluoxetine, Paroxetine, Sertraline, Venlafaxine, Desvenlafaxine, and Duloxetine.

12. 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or pharmaceutically acceptable salts thereof for use according to any one of claims 1-11, wherein said patient has a total score of above 30 in an Oxford Depression Questionnaire (ODQ).

13. 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or pharmaceutically acceptable salts thereof for use according to any one of claims 1-12, wherein said pharmaceutically acceptable salt is selected from the group consisting of hydrobromide salt, lactic acid salt, and pyroglutamate salt.

14. 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or pharmaceutically acceptable salts thereof for use according to claim 13, wherein said pharmaceutically acceptable salt is selected from the hydrobromide (α) salt, hydrobromide (β) salt, or hydrobromide (γ) salt.

15. 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or pharmaceutically acceptable salts thereof for use according to any one of claims 1-14 , wherein 1-[2-(2,4-

dimethylphenylsulfanyl)-phenyl]piperazine or pharmaceutically acceptable salts thereof is administered in a unit dose of about 5 mg, about 10 mg, or about 20 mg of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.

16. 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or pharmaceutically acceptable salts thereof for use according to any one of the preceding claims 1-15, wherein 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or pharmaceutically acceptable salts thereof is administered in a dose of about 5 mg/day, about 10mg/day, or about 20mg/day of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.

17. 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or pharmaceutically acceptable salts thereof for use according to any one of the preceding claims 1-16, wherein 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or pharmaceutically acceptable salts thereof is administered as oral tablets or oral drops.